EFElena Ferrer-Sistach

Elena Ferrer-Sistach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elena Ferrer-Sistach has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic impact of moderate secondary mitral regurgitation after optimized medical therapy in heart failure

    by Cristina Ferrero, Pau Codina, Josep Lupón, María Ruiz-Cueto, Elisabet Zamora, Andrea Borrellas, Cinta Llibre, Clara Badia-Molins, Andrea Carrete, Evelyn Santiago-Vacas, et al.

    Background and Aims: The prognostic significance of moderate secondary mitral regurgitation (MR) after optimized guideline-directed medical therapy (GDMT) in heart failure (HF) remains uncertain. Methods: We analysed 2468 ambulatory HF patients with paired transthoracic echocardiography at baseline and after 12 months of optimized GDMT. The primary composite was all-cause death or first heart failure hospitalization (HFH). Secondary endpoints included all-cause mortality and recurrent HFHs. Results: The mean age of patients was 66.2 ± 12.5 years, 70.6% were male, and the mean baseline left ventricular ejection fraction was 36.1% ± 13.6%. At 12 months, 80.5% of patients had no/mild MR, 15.6% had moderate MR, and 3.9% had severe MR. During a median 6.9-year follow-up, 1240 patients experienced the primary endpoint. Compared with no/mild MR, both moderate and severe MR at 12 months were independently associated with a higher risk of the primary composite endpoint [moderate: hazard ratio (HR) 1.69, 95% confidence interval (CI) 1.47–1.95; severe: HR 1.81, 95% CI 1.44–2.29; both P < .001). Moderate MR was also independently associated with increased all-cause mortality (HR 1.54, 95% CI 1.32–1.79; P < .001) and recurrent HFHs (incidence rate ratio 2.17, 95% CI 1.81–2.60). Heart failure hospitalization rates were 9.03, 20.0, and 26.1 per 100 person-years in patients with no/mild, moderate, and severe MR, respectively. Among patients with moderate MR at 12 months, outcomes did not differ according to baseline MR severity. Conclusions: In this large-scale study, residual moderate secondary MR after 12 months of optimized GDMT was common and was independently associated with increased long-term mortality and HFHs.

  • Non-invasive assessment of left atrial pressure in patients with heart failure: head-to-head comparison of novel machine learning–based echocardiographic tool with a wireless pulmonary artery sensor

    by Stefania Duca, Marta Cosano, Carlo Guarino, Evelyn Santiago-Vacas, Jimmy L Su, Claudia Escabia, Elena Ferrer-Sistach, Antoni Bayés-Genís, Victoria Delgado

  • Open Access

    Artificial intelligence for aortic valve calcium score quantification by echocardiography

    by Pere Lopez-Gutierrez, Alberto Morales-Galán, Laura Galian-Gay, Juan Garrido-Oliver, Lydia Dux-Santoy, Neil J Craig, Zi Ye, Josep M. Alegret, Javier Bermejo, Francisco Calvo-Iglesias, et al.

    Background: Aortic valve calcification (AVC), as measured by gold-standard computed tomography (CT) Agatston score, provides an anatomic assessment of aortic stenosis (AS) severity and is a key predictor of AS progression and need for valve replacement. AVC detection and quantification from transthoracic echocardiography (TTE) could expand AS early diagnosis and risk stratification, currently limited by CT availability and radiation exposure. Methods: A multi-view video-based deep learning framework was developed using 1166 TTE aortic valve videos from 187 TTE studies acquired in 110 patients with available AVC score by CT. EchoAVC architecture includes a feature extraction model followed by a quality-aware model that aggregates video-level information to obtain patient-level predictions for AVC detection and quantification (score). The framework was validated internally with 173 TTE studies from 86 patients across seven centres, and externally using 430 TTE studies from 280 patients across four different centres. The associations between EchoAVC estimations and AS severity, progression, and need for aortic valve replacement were examined. Results: EchoAVC demonstrated excellent performance in AVC detection (AUROC 0.98, accuracy 94.4%), and quantification (R = 0.64) in the external multi-centre testing set. EchoAVC score was correlated with echocardiographic AS severity descriptors, including aortic valve mean pressure gradient (ρ = 0.749) and peak velocity (ρ = 0.757), and predicted future increase in mean pressure gradient (ρ = 0.382), peak velocity (ρ = 0.433) and calcium score by CT (ρ = 0.650). In 361 patients followed for a median of 3.8 years, 139 underwent aortic valve replacement. Baseline presence and extent of AVC as predicted by EchoAVC showed strong risk-stratification power for aortic valve replacement, remarkably in line with those obtained by CT, and incremental over TTE AS descriptors. EchoAVC was further tested in routine clinical practice images, confirming strong associations with AS severity and progression, including stratification for incident AS in previously unaffected individuals (p<0.001). Conclusions: EchoAVC enables accurate and non-invasive detection and quantification of AVC, offering substantial diagnostic and prognostic value for aortic stenosis progression and need for valve replacement. This technique holds promise as a scalable tool for early detection and clinical management of aortic valve stenosis. Clinical Perspective: What Is New?: * Aortic valve calcification can be detected and quantified on standard, two-dimensional transthoracic echocardiography * EchoAVC score is associated with echocardiographic metrics of aortic stenosis severity * EchoAVC predicts progressive increase in aortic stenosis severity and need for aortic valve replacement What Are the Clinical Implications?: * This openly available deep learning framework can be used to estimate aortic valve calcium in patients at risk of or presenting aortic stenosis to predict aortic stenosis progression * EchoAVC may help identify patients likely to have high aortic valve calcium and prioritize them for confirmatory CT assessment, thereby supporting earlier identification of calcific aortic valve disease in clinical pathways.

  • Left atrial remodelling and function in various left ventricular hypertrophic phenotypes

    by Martina De Raffele, Albert Teis, German Cediel, Jerremy Weerts, Cristina Conte, Gladys Juncà, Gizem Kasa, Elena Ferrer-Sistach, Matteo Bertini, Antoni Bayes-Genis, et al.

    Aims: How the underlying aetiology and pathophysiology of left ventricular (LV) hypertrophy affects left atrial (LA) remodelling and function remains unexplored. The present study aims to investigate the influence of various hypertrophic phenotypes on LA remodelling and function. Methods and results: Patients with LV hypertrophy who underwent cardiac magnetic resonance (CMR) were compared to a control group. CMR data were analysed retrospectively to assess LA strain, volume, sphericity, and left atrioventricular coupling index (LACI). Independent clinical associates of LA strain were assessed using multivariable linear regression analysis. A total of 375 individuals were included: 148 with hypertrophic cardiomyopathy (HCM), 35 with cardiac amyloidosis (CA), 41 with hypertensive (HTN) heart disease, 97 with severe asymptomatic aortic stenosis (AS), and 54 with normal CMR. Indexed LA end-systolic (iLVmax), diastolic volumes, and LA sphericity were the largest in patients with CA (59.1 ± 16.9 mL/m2, 46.8 ± 16.4 mL/m2, and 83.2 ± 2.1%, respectively). Patients with CA presented a higher LACI when compared with other groups (58 ± 2% vs. 42 ± 2% in HCM, 39 ± 2% in HTN heart disease, 37 ± 2% in AS, and 22 ± 1% in normal), while no differences were observed across others. Patients with CA showed the lowest LA reservoir [9.6% (0.6–18.6%)] and booster strain (9.1 ± 5.4%), whereas no differences were observed across other groups. LACI and iLAVmax were independently correlated with LA reservoir (β = 0.15 and β = −39.33, respectively), LA conduit (β = 0.08 and β = −17.08, respectively), and LA booster strains (β = 0.1 and β = −28.69, respectively). LA sphericity was independently correlated with LA reservoir strain (β = −0.51). Finally, LV global longitudinal strain was independently correlated with LA reservoir (β = −0.43), conduit (β = −0.20), and booster strain (β = −0.24). Conclusion: LA characteristics differ among LV hypertrophic phenotypes. LACI and iLAVmax are independently correlated with LA function, while LA sphericity correlates independently with LA reservoir strain.


  • From left ventricular outflow tract obstruction to mitral obstruction

    by Mireia Llevadot, Elena Ferrer-Sistach, Lorenzo Niro, Luis Delgado, Victoria Delgado

    Mireia Llevadot, MD, Elena Ferrer-Sistach, MD, PhD, Lorenzo Niro, MD, Luis Delgado, MD, Victoria Delgado, MD, PhD; From Left Ventricular Outflow Tract Obst

  • Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial

    by Arturo Evangelista, Laura Galian-Gay, Andrea Guala, Gisela Teixido-Tura, Francisco Calvo-Iglesias, Teresa Sevilla, Javier Bermejo, Irene Méndez, Violeta Sánchez, Juan M. Robledo Carmona, et al.

    BACKGROUND: Ascending aorta dilation and aortic valve degeneration are common complications in patients with bicuspid aortic valve. Several retrospective studies have suggested the benefit of statins in reducing these complications. This study aimed to determine whether atorvastatin treatment is effective in reducing the growth of aortic diameters in bicuspid aortic valve and if it slows the progression of valve calcification. METHODS: In a randomized clinical trial, 220 patients with bicuspid aortic valve (43 women; 46±13 years of age) were included and treated with either 20 mg of atorvastatin per day or placebo for 3 years. Inclusion criteria were ≥18 years of age, nonsevere valvular dysfunction, nonsevere valve calcification, and ascending aorta diameter ≤50 mm. Computed tomography and echocardiography studies were performed at baseline and after 3 years of treatment. RESULTS: During follow-up, 28 patients (12.7%) discontinued medical treatment (15 on atorvastatin and 13 taking placebo). Thus, 192 patients completed the 36 months of treatment. Low-density lipoprotein cholesterol levels decreased significantly in the atorvastatin group (median [interquartile range], −30 mg/dL [−51.65 to −1.75 mg/dL] versus 6 mg/dL [−4, 22.5 mg/dL]; P P =0.613). Similarly, no significant differences were found for the progression of the aortic valve calcium score ( P =0.167) or valvular dysfunction. CONCLUSIONS: Among patients with bicuspid aortic valve without severe valvular dysfunction, atorvastatin treatment was not effective in reducing the progression of ascending aorta dilation and aortic valve calcification during 3 years of treatment despite a significant reduction in low-density lipoprotein cholesterol levels. REGISTRATION: URL: https://www.clinicaltrialsregister.eu ; Unique identifier: 2015-001808-57. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02679261.


  • Clinical and prognostic implications of left ventricular dilatation in heart failure

    by Gizem Kasa, Albert Teis, Gladys Juncà, Alberto Aimo, Josep Lupón, German Cediel, Evelyn Santiago-Vacas, Pau Codina, Elena Ferrer-Sistach, Nuria Vallejo-Camazón, et al.

    To assess the agreement between left ventricular end-diastolic diameter index (LVEDDi) and volume index (LVEDVi) to define LV dilatation and to investigate the respective prognostic implications in patients with heart failure (HF). Patients with HF symptoms and LV ejection fraction (LVEF) < 50% undergoing cardiac magnetic resonance were evaluated retrospectively. LV dilatation was defined as LVEDDi or LVEDVi above the upper normal limit according to published reference values. Patients were followed up for the combined endpoint of cardiovascular death or HF hospitalization during 5 years. A total of 564 patients (median age 64 years; 79% men) were included. LVEDDi had a modest correlation with LVEDVi (r = 0.682, P < 0.001). LV dilatation was noted in 84% of patients using LVEDVi-based definition and in 73% using LVEDDi-based definition, whereas 20% of patients displayed discordant definitions of LV dilatation. During a median follow-up of 2.8 years, patients with both dilated LVEDDi and LVEDVi had the highest cumulative event rate (HR 3.00, 95% CI 1.15–7.81, P = 0.024). Both LVEDDi and LVEDVi were independently associated with the primary outcome (hazard ratio 3.29, 95%, P < 0.001 and 2.8, P = 0.009; respectively). The majority of patients with HF and LVEF < 50% present both increased LVEDDi and LVEDVi whereas 20% show discordant linear and volumetric definitions of LV dilatation. Patients with increased LVEDDi and LVEDVi have the worst clinical outcomes suggesting that the assessment of these two metrics is needed for better risk stratification. Left ventricular dilatation based on linear dimension (left ventricular end-diastolic diameter) or volumetric dimension (left ventricular end-diastolic volume) vs prognosis. Panel A shows the 3-chamber reconstruction of the left ventricle from a cardiac magnetic resonance (CMR) cine image. The dotted line demarcates the plane where the short-axis of the left ventricle is acquired and where the left ventricular endi-diastolic diameter is measured and indexed , LVEDDi). The 4-chamber view of the left ventricle is shown and the left ventricular end-diastolic volume is measured from stacks of short-axis and indexed to body surface area (LVEDVi). In this case, the LVEDDi is non-dilated whereas the LVEDVi is dilated. Panel B shows the CMR data of a patient with dilated left ventricle based on LVEDDi and LVEDVi. Panel C shows the correlation between LVEDDi and LVEDVi and the 4 groups of patients based on the dilatation of one or the other dimension or both. Panel D shows the cumulative survival curves for each group of patients.


  • Atrial functional mitral regurgitation: the tip of the iceberg

    by Cristina Conte, Cristina Campoamor Cela, Victoria Delgado, Elena Ferrer-Sistach

    Cristina Conte, MD, Cristina Campoamor Cela, Victoria Delgado, MD, PhD, Elena Ferrer-Sistach, MD, PhD; Atrial functional mitral regurgitation: the tip of the ic


  • Transcatheter intervention in massive tricuspid regurgitation: in for a penny, in for a pound!

    by Mariana Martino, Cristina Conte, Elena Ferrer-Sistach, Victoria Vilalta, Victoria Delgado

    Mariana Martino, MD, Cristina Conte, MD, Elena Ferrer-Sistach, MD, PhD, Victoria Vilalta, MD, PhD, Victoria Delgado, MD, PhD; Transcatheter intervention in mass

  • Preload dependence of pulmonary haemodynamics and right ventricular performance

    by Francisco Gual-Capllonch, Josep Lupón, Ioana Bancu, Fredzzia Graterol, Elena Ferrer-Sistach, Albert Teis, Evelyn Santiago-Vacas, Nuria Vallejo, Gladys Juncà, Antoni Bayes-Genis

    Aims Systolic pulmonary artery pressure (SPAP) and right heart adaptation in relation to pre-existing preload are often disregarded. To determine volume-related changes in the pulmonary-right ventricle (RV) unit and the preload dependence of its components, we analysed pulmonary haemodynamics and right ventricular performance, taking advantage of the plasma volume removal associated to haemodialysis (HD). Methods and results Fifty-three stable patients on chronic HD with LVEF > 50% and without heart failure were recruited (mean age 63.0 ± 12.4 years; 31.2% women; hypertension in 89% and diabetes in 53%) and evaluated just before and after HD (mean ultrafiltration volume 2.4 ± 0.7 l). SPAP from both times were available in 39 patients. After HD, SPAP decreased (42.2 ± 12.6 to 33.7 ± 11.6 mmHg, p < 0.001) without modification of non-invasive pulmonary vascular resistance (1.75 ± 0.44 to 1.75 ± 0.40 eWU, p = 0.94). Age and drop in the E/eʹ ratio were the variables associated with greater reduction in PASP (p = 0.022 and p = 0.049, respectively). A significant reduction of right chamber sizes was observed, along with a diminution in measures of RV contractility, excluding RV longitudinal strain. Functional tricuspid regurgitation (FTR) diminution was observed in 26% of patients, occurring in every case with more than mild FTR. On multivariate analyses, left atrial size was the only predictor of pulmonary hypertension (defined as SPAP > 40 mmHg) (OR 1.29 (1.07–1.56), p = 0.006). Conclusion Rapid volemic changes may affect FTR grading, RV size and contractility, with RV longitudinal strain being less variable than conventional parameters. SPAP decreases after HD, and this reduction is related to age and greater diminution of the E/eʹ ratio. Graphic abstract